NTLA NTLA

Intellia Therapeutics Stock Price

116.43
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
116.43
Volume 0
Bid Price 115.50
Ask Price 118.00
News -
Day High

Low
43.86

52 Week Range

High
202.73

Day Low
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Intellia Therapeutics Inc NTLA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 116.43 19:00:00
Open Price Low Price High Price Close Price Prev Close
116.43
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 116.43 USD

Period:

Draw Mode:

Intellia Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 8.66B 74.42M 62.08M $ 57.99M $ - -2.41 -29.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -273.95k 2.60%

more financials information »

Intellia Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NTLA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week106.50120.8591.99108.27914,0569.939.32%
1 Month128.25138.3591.99117.76758,502-11.82-9.22%
3 Months152.51158.8491.99129.91751,568-36.08-23.66%
6 Months80.33202.7374.65139.401,466,94236.1044.94%
1 Year48.70202.7343.86103.161,488,19967.73139.08%
3 Years15.84202.739.1861.54971,594100.59635.04%
5 Years15.52202.739.1850.35824,797100.91650.19%

Intellia Therapeutics Description

Intellia Therapeutics Inc is a genome editing company. It is focused on developing proprietary, potentially curative CRISPR/Cas9-based therapeutics. Its pipeline includes in vivo development programs targeting genetic diseases, including transthyretin amyloidosis and hereditary angioedema, and ex vivo programs which include Acute Myeloid Leukemia.


Your Recent History
NASDAQ
NTLA
Intellia T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.